Edotecarin: A novel topoisomerase I inhibitor

Clinical Colorectal Cancer

Volumn 5, Issue 1, 2005, Pages 27-36

  Saif, M Wasif ^a   Diasio, Robert B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Camptothecin; Pharmacogenetics; Pharmacokinetics; Phase II trials

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEXAMETHASONE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EDOTECARIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN P; GRANISETRON; IRINOTECAN; L 753049; LOMUSTINE; OXALIPLATIN; PACLITAXEL; PROTEIN KINASE; SINGLE STRANDED DNA; STAUROSPORINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; CARBAZOLE DERIVATIVE; INDOLE DERIVATIVE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DNA BINDING; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG FEVER; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; ILEUS; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LEUKEMIA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PHARYNX CANCER; PHLEBITIS; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TERATOGENICITY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; URINARY TRACT INFECTION; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAZOLES; CELL CYCLE; CLINICAL TRIALS; DIARRHEA; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; NEOPLASMS;

EID: 21844454211     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.014     Document Type: Review

References (25)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54:665-697.
2. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1969; 88:3888-3890.
3. Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin sodium (NSC-100880). Cancer Chemother Rep 1972; 56:515-521.
4. Sawada S, Yokokura T, Miyasaka T. Synthesis of CPT-11 (irinotecan hydrochloride trihydrate). Ann N Y Acad Sci 1996; 803:13-28.
5. Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan. Ann N Y Acad Sci 1996; 803:292-305.
6. Takeda K, Negoro S, Sawa T, et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 2003; 4:224-228.
7. Giles FJ, Cortes JE, Thomas DA, et al. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 2002; 8:2134-2141.
8. Ohkubo M, Nishimura T, Kawamoto H, et al. Synthesis and biological activities of NB-506 analogues modified at the glucose group. Bioorg Med Chem Lett 2000; 10:419-422.
9. Arakawa H, Iguchi T, Morita M, et al. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1, 11-dihydroxy-13-(beta-D-glucopyranosyl)- 5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res 1995; 55:1316-1320.
10. Arakawa H, Morita M, Kodera T, et al. In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn J Cancer Res 1999; 90:1163-1170.
11. Yoshinari T, Ohkubo M, Fukasawa K, et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999; 59:4271-4275.
12. Yoshinari T, Matsumoto M, Arakawa H, et al. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13- (β-D-glucopyranosyl)5H-indolo[2,3-a]pyrrolo[3, 4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanism of cell line-selective cytotoxicity. Cancer Res 1995; 55:1310-1315.
13. Fukasawa K, Komatani H, Hara Y, et al. Sequence-selective DNA cleavage by topoisomerase I poison, NB-506. Int J Cancer 1998; 75:145-150.
14. Ohkubo M, Kojiri K, Kondo H, et al. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Bioorg Med Chem Lett 1999; 9:1219-1224.
15. Pollack S, Young L, Bilsland J, et al. The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor. Mol Pharmacol 1999; 56:185-195.
16. Cavazos CM, Keir ST, Yoshinari T, et al. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(-D-glucopyranosyl)- 5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmocol 2001; 48:250-254.
17. Komatani H, Kotani H, Hara Y, et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 2001; 61:2827-2832.
18. Kanzawa F, Nishio K, Kubota N, et al. Antitumor activities of a new indolcarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res 1995; 55:2806-2813.
19. Komatani H, Morita M, Sakaizumi N, et al. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. Cancer Res 1999; 59:2701-2708.
20. Denny WA. Edotecarin. Drugs 2004; 7:173-177.
21. Peck R. Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc Am Soc Clin Oncol 2000; 19:197a (Abstract #767).
22. Lewis L, Perez R, Petros W, et al. A phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule. Proc Am Soc Clin Oncol 2000; 19:177a (Abstract #688).
23. Yamada Y, Yamamoto N, Shimoyama T, et al. Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc Am Soc Clin Oncol 2002; 21:97a (Abstract #385).
24. Perez R, Hurwitz H, Nahum K, et al. Phase II trials of J-107088, a non-camptothecin topoisomerase I inhibitor, in irinotecan naive/ refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:159a (Abstract #632).
25. Nahum K, Shiba D, Padavanija P, et al. Phase II efficacy and tolerability of edotecarin (J-107088) in patients with irinotecan-naive metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22:274 (Abstract #1099).